mental health – Talk Bio

Newleos Therapeutics Launches with $93.5M to Advance Novel Neuropsychiatric Treatments

2 months ago talkbio0Tagged Anxiety Disorders, assets, Funding, GABA Modulators, mental health, Neuropsychiatry, Newleos, Roche (company), Series, Substance Use Disorders

Newleos Therapeutics, mental health, neuropsychiatry, Roche assets, Series A funding, anxiety disorders, substance use disorders, GABA modulators

Negev Labs Unveils Next-Gen Psychedelic Therapies with Non-Hallucinogenic Neuroplastogens

4 months ago talkbio0Tagged Biotechnology, Builder, Hallucinogens, Laboratory test finding, mental health, Negev, neuroplastogens, non-hallucinogenic, psychedelic therapies

Negev Labs, neuroplastogens, psychedelic therapies, non-hallucinogenic psychedelics, mental health treatments, biotechnology company builder

Cybin’s Psychedelic Breakthroughs: Advancing Mental Health Treatments

5 months ago talkbio0Tagged Breakthrough Therapy, Clinical Trials, Cybin, Hallucinogens, Identifier, mental health, N,N-Dimethyltryptamine, Psilocybin, United States Food and Drug Administration

Cybin, psychedelic therapeutics, mental health treatments, deuterated psilocybin, deuterated DMT, clinical trials, FDA Breakthrough Therapy Designation.

Semaglutide and Mental Health: A Complex Relationship

8 months ago talkbio0Tagged Diabetes, Glucagon-Like Peptide 1, ideation, mental health, semaglutide, Suicidal

semaglutide, mental health, suicidal ideation, GLP-1 drugs, weight loss, diabetes

Rapport Neuroscience Biotech Aims for Expansion with Initial Public Offering

11 months ago talkbio0Tagged clinical-stage, expansion, IPO, mental health, nervous system disorder, Neuroscience discipline, Rapport

Rapport, neuroscience, biotech, IPO, clinical-stage, expansion, pharmaceuticals, neurological disorders, mental health

AbbVie and Gilgamesh Pharmaceuticals Join Forces in a $2 Billion Psychedelic Drug Development Partnership

11 months ago talkbio0Tagged AbbVie, Drug Development, Gilgamesh, Hallucinogens, Mental disorders, mental health, Neuroscience discipline, next-generation

AbbVie, Gilgamesh Pharmaceuticals, psychiatric disorders, psychedelic drugs, drug development, mental health, next-generation treatments, neuroscience, pharmaceutical collaboration, $2 billion deal.

Uzedy, Teva, and MedinCell’s Collaborative Effort Yields Success in Phase 3 Trials for Long-Acting Schizophrenia Treatment

12 months ago talkbio0Tagged Collaboration, Injectables, long-acting, Medincell, mental health, Neuroscience discipline, Phase 3 trials, Psychiatry Specialty, Schizophrenia, Teva, Uzedy

Uzedy, Teva, MedinCell, long-acting, schizophrenia, phase 3 trials, treatment, collaboration, mental health, neuroscience, psychiatry, injectable medication.

FDA Panel to Evaluate Lykos’ Innovative Psychedelic Treatment for Post-Traumatic Stress Disorder

12 months ago talkbio0Tagged Clinical Trials, Lykos ', mental health, mental health breakthrough, Post-Traumatic Stress Disorder, psychedelic therapy, review panel, United States Food and Drug Administration

FDA, Lykos, psychedelic therapy, PTSD, mental health, clinical trials, review panel, innovative treatment, mental health breakthrough.

Novo Holdings Supports Reunion Neuroscience’s $103M Series A Funding for Pioneering Psychedelic Clinical Trials

12 months ago talkbio0Tagged Biotechnology, Funding, Health care facility, Holdings, Investments, mental health, mental health innovation, Neuroscience discipline, psychedelic clinical trials, Reunion Island, Series, venture

Novo Holdings, Reunion Neuroscience, Series A funding, psychedelic clinical trials, mental health treatments, mental health innovation, venture capital, biotechnology, healthcare investments.

Reunion Neuroscience Secures $103 Million to Advance Psychedelic Therapies for Patients

12 months ago talkbio0Tagged Clinical Trials, Industry, mental health, mental health innovation, Neuroscience discipline, patient care, psychedelic therapies, Reunion Island

Reunion Neuroscience, psychedelic therapies, mental health, fundraising, clinical trials, mental health treatments, alternative therapies, mental health innovation, patient care, biotech industry.